The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology

被引：2

作者：

Tayeb, Haythum O. ^{[1
]}

Khallaf, Roaa A. ^{[2
]}

Muayqil, Taim A. ^{[3
]}

Alkeridy, Walid A. ^{[4
]}

Alibrahim, Fawwaz S. ^{[5
]}

Alfaify, Omar A. ^{[6
]}

Qadi, Najeeb ^{[7
]}

Tarazi, Frank, I ^{[8
,9
]}

机构：

[1] King Abdulaziz Univ, Neurosci Res Unit & Mind & Brain Studies Initiat, Div Neurol,Fac Med, Dept Internal Med, Jeddah, Saudi Arabia

[2] King Saud Univ, Dept Neurol, Neurosci Ctr, Riyadh, Saudi Arabia

[3] King Saud Univ, Neurol Unit, Riyadh, Saudi Arabia

[4] King Saud Univ, Dept Med, Coll Med, Riyadh, Saudi Arabia

[5] King Faisal Specialist Hosp & Res Ctr, Neurol Div, Dept Med,Minist Natl Guard Hlth Affairs, King Abdulaziz Med City, Riyadh, Saudi Arabia

[6] King Faisal Specialist Hosp & Res Ctr, Dept Neurol, Prince Sultan Mil Med City, Riyadh, Saudi Arabia

[7] King Faisal Specialist Hosp & Res Ctr, Neurosci Ctr, Riyadh, Saudi Arabia

[8] Harvard Med Sch, Dept Psychiat & Neurosci, Belmont, MA USA

[9] McLean Hosp, 115 Mill St, Belmont, MA 02178 USA

来源：

NEUROSCIENCES | 2023年 / 28卷 / 02期

关键词：

CARE; DEMENTIA; VERSION;

D O I：

10.17712/nsj.2023.2.20220133

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Alzheimer Disease (AD) constitutes a major global healthcare problem. Standard AD pharmacotherapies offer only modest transient cognitive and behavioral benefits. Aducanumab, an amyloid monoclonal antibody, was the first disease modifying agent to be approved for AD treatment. However, concerns about its efficacy and side effects led regulatory institutions around the world to restrict its use. Lecanemab was the second amyloid antibody to receive accelerated approval for use in early AD. This review and consensus statement was prepared by the Saudi Chapter of Cognitive and Behavioral Neurology to review the current developments in AD immunotherapies from a Saudi perspective. We outline recommendations with regards to offering aducanumab and other future immunotherapies to Saudi AD patients. We describe resources, infrastructure, research, and clinical practice changes that must be attained to transform the patient journey and clinical pathways of AD in Saudi Arabia to enable offering AD immunotherapies in Saudi Arabia.

引用

页码：77 / 84

页数：8

共 50 条

[41] Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project
Ritchie, Karen
Ropacki, Michael
Albala, Bruce
Harrison, John
Kaye, Jeffrey
Kramer, Joel
Randolph, Christopher
Ritchie, Craig W.
ALZHEIMERS & DEMENTIA, 2017, 13 (02) : 186 - 195
[42] Perception and barriers to the use of cognitive-behavioral therapy in the treatment of depression in primary healthcare centers and family medicine clinics in Saudi Arabia
AlHadi, AhmadN
AlGhofili, Hesham H.
Almujaiwel, Nasser A.
Alsweirky, Helmi M.
Albeshr, Mohammed F.
Almogbel, Gassan T.
JOURNAL OF FAMILY AND COMMUNITY MEDICINE, 2021, 28 (02): : 77 - 84
[43] Public awareness, knowledge and attitude toward Alzheimer's disease in Aseer region, Saudi Arabia - community based cross sectional study
Alqahtani, Ali
Alqahtani, Mohammed
Zarbah, Abdulmajeed
ALAhmari, Tariq
Alhazzani, Adel
NEUROLOGY, 2017, 88
[44] Awareness and Perception Toward Alzheimer's Disease Among Residents Living in the Jazan Province, Saudi Arabia: A Cross-Sectional Study
Hakami, Faisal
Madkhali, Mohammed Ali
Saleh, Eman
Ayoub, Raum
Moafa, Sarah
Moafa, Akram
Alnami, Bushra
Maashi, Bushra
Khubrani, Saad
Busayli, Wafa
Alhazmi, Abdulaziz
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
[45] Prevalence of Obesity among Male Adolescents in Arar Saudi Arabia: Future Risk of Cardiovascular Disease (vol 40, pg 182, 2015)
Alenazi, S. A.
Koura, H. M.
Zaki, S. M.
Mohamed, A. H.
INDIAN JOURNAL OF COMMUNITY MEDICINE, 2019, 44 (03) : 293 - 293
[46] Evaluation of healthcare professionals' knowledge of Alzheimer's disease in government hospitals and healthcare centers: A cross-sectional study in Jeddah, Saudi Arabia
Alzahrani, Yahya A.
Harbi, Maan H.
Almalki, Adel G.
Althomali, Rana A.
Alorabi, Roaa F.
Basulyman, Bashaer S.
Alansari, Khawla A.
Alzahrani, Jasser A.
Alzahrani, Dalia A.
Asuhaimi, Ibrahim A.
Alzahrani, Abdullah M.
Alkatheeri, Ayed A.
MEDICINE, 2025, 104 (09)
[47] Administration and Monitoring Burden of High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis: A Delphi Consensus of Clinical Experts from Saudi Arabia
Makkawi, Seraj
Abulaban, Ahmad
Al Malik, Yaser
Alshehri, Ebtesam
Althobaiti, Ahmed
Aljarallah, Salman
Elboghdady, Ahmed
Alhajjar, Lynn
Shami, Sahar
Bohlega, Saeed
Aljumah, Mohammed
NEUROLOGY AND THERAPY, 2025, 14 (01) : 413 - 427
[48] Comprehensive Management of Daily Living Activities, behavioral and Psychological Symptoms, and Cognitive Function in Patients with Alzheimer's Disease: A Chinese Consensus on the Comprehensive Management of Alzheimer's Disease
Jia, Jianjun
Xu, Jun
Liu, Jun
Wang, Yongjun
Wang, Yanjiang
Cao, Yunpeng
Guo, Qihao
Qu, Qiuming
Wei, Cuibai
Wei, Wenshi
Zhang, Junjian
Yu, Enyan
NEUROSCIENCE BULLETIN, 2021, 37 (07) : 1025 - 1038
[49] Comprehensive Management of Daily Living Activities, behavioral and Psychological Symptoms, and Cognitive Function in Patients with Alzheimer's Disease: A Chinese Consensus on the Comprehensive Management of Alzheimer's Disease
Jianjun Jia
Jun Xu
Jun Liu
Yongjun Wang
Yanjiang Wang
Yunpeng Cao
Qihao Guo
Qiuming Qu
Cuibai Wei
Wenshi Wei
Junjian Zhang
Enyan Yu
Neuroscience Bulletin, 2021, 37 : 1025 - 1038
[50] European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment
Frederiksen, Kristian Steen
Nielsen, T. Rune
Winblad, Bengt
Schmidt, Reinhold
Kramberger, Milica G.
Jones, Roy W.
Hort, Jakub
Grimmer, Timo
Georges, Jean
Frolich, Lutz
Engelborghs, Sebastiaan
Dubois, Bruno
Waldemar, Gunhild
EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (07) : 2147 - 2155

← 1 2 3 4 5 →